GE Healthcare has introduced its Clariscan, a gadoteric acid, in the European market to grow its range of MRI contrast media options among patients and radiologists. Clariscan is a gadolinium-based contrast agent (GBCA) designed to support effective visualization of abnormalities in the brain, spine, and associated tissues, and will be provided alongside GE Healthcare's comprehensive support services and solutions to healthcare practitioners worldwide.
GBCAs offer improved contrast between normal and pathological tissue to enable rapid detection of abnormalities. Macrocyclic Clariscan, manufactured using a proprietary GE process, is expected to extend choice for radiology professionals, backed by one of the well-established quality, reliability, and surrounding services offered by GE.
Clariscan will be available in a range of doses in vials and pre-filled syringes. It is the latest in a line of products and services provided by GE Healthcare to the radiology community, which include a wide range of contrast media as well as a portfolio of systems and products across MRI, X-ray/CT, and ultrasound modalities.
Demand for contrast media has significantly increased over the past decade due to rapid procedural advancements in MR imaging, elevating the importance of uninterrupted and sustainable product supply, as well as meeting the individual needs of patients undergoing diagnostic procedures. The company has invested several millions in its worldwide supply network to increase manufacturing capacity.